TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 27072971

Group type: EXPERIMENTAL
Intervention: Plasma‐Lyte A 100 mL (P100 group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Plasma‐Lyte A 250 mL (P250 group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Plasma‐Lyte A 500 mL (P500 group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: 0.9% saline 500 mL (N500 group)
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Gelofusine 500 mL (G500 group)
Number of subjects: 200
Study: 25518300

Group type: EXPERIMENTAL
Intervention: Electrocoagulation
Number of subjects: 50

Group type: COMPARATOR
Intervention: Suture
Number of subjects: 50
Study: 22266043

Group type: EXPERIMENTAL
Intervention: Pemetrexed in combination with cisplatin
Number of subjects: 2388

Group type: EXPERIMENTAL
Intervention: Single-agent pemetrexed
Number of subjects: 2388

Group type: COMPARATOR
Intervention: Cisplatin and gemcitabine
Number of subjects: 2388

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2388
Study: 20637149

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1‐0.3 mg/kg)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Diazepam (0.3‐0.5 mg/kg)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Midazolam (maintenance dose 1‐8 mg/kg per hour)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Diazepam (maintenance dose 0.5‐1 mg/kg per hour)
Number of subjects: 120
Study: 17970410

Group type: EXPERIMENTAL
Intervention: Rehabilitative ultrasound imaging (RUSI) as a feedback tool
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rehabilitative ultrasound imaging (RUSI)
Number of subjects: 0
Study: 15731556

Group type: EXPERIMENTAL
Intervention: Bendrofluazide 2.5 mg daily
Number of subjects: 37

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 37
Study: 12053548

Group type: EXPERIMENTAL
Intervention: Steroids for diffuse proliferative extracapillary forms or moderately severe NIgA with normal renal function
Number of subjects: 0
Study: 9337359

Group type: EXPERIMENTAL
Intervention: Left lateral decubitus (LLD) position
Number of subjects: 0

Group type: COMPARATOR
Intervention: Kneeling (K) position
Number of subjects: 0
Study: 7932136

Group type: EXPERIMENTAL
Intervention: 5.0 x 6.0 mm ovoid PMMA lens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 7.0 mm round PMMA lens
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 5.5 mm round PMMA lens
Number of subjects: 0

Group type: COMPARATOR
Intervention: All IOL groups
Number of subjects: 0
Study: 3283789

Group type: EXPERIMENTAL
Intervention: Midazolam (0.1 mg/kg IV)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Diazepam (0.2 mg/kg IV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Midazolam and Diazepam
Number of subjects: 0
Study: 28605148

Group type: EXPERIMENTAL
Intervention: Dynamic Core Stability program (DCS)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 31
Study: 27839852

Group type: EXPERIMENTAL
Intervention: Bioethanol CleanCook stoves
Number of subjects: 271

Group type: COMPARATOR
Intervention: Firewood/Kerosene stove (Control)
Number of subjects: 271
Study: 26181087

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol (400 micrograms every 3 hours for up to six doses)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Buccal misoprostol (400 micrograms every 3 hours for up to six doses)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol
Number of subjects: 130

Group type: COMPARATOR
Intervention: Buccal misoprostol
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Vaginal misoprostol and Buccal misoprostol
Number of subjects: 130
Study: 23551925

Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 21348568

Group type: EXPERIMENTAL
Intervention: Mailed guaiac‐based fecal occult blood tests (gFOBTs)
Number of subjects: 7053

Group type: COMPARATOR
Intervention: Visit-based colorectal cancer screening (Control group 1)
Number of subjects: 7053

Group type: COMPARATOR
Intervention: Visit-based colorectal cancer screening (Control group 2)
Number of subjects: 7053

Group type: COMPARATOR
Intervention: Visit-based colorectal cancer screening (Control group 3)
Number of subjects: 7053
Study: 18449422

Group type: EXPERIMENTAL
Intervention: DDAVP administration
Number of subjects: 36
Study: 16713541

Group type: EXPERIMENTAL
Intervention: Adjuvant 5-FU-based chemoradiotherapy
Number of subjects: 607

Group type: COMPARATOR
Intervention: Surgery only
Number of subjects: 607
Study: 14517521

Group type: EXPERIMENTAL
Intervention: i.v.GG plus corticosteroids (G+S group)
Number of subjects: 32

Group type: COMPARATOR
Intervention: i.v.GG alone (G group)
Number of subjects: 32
Study: 10634736

Group type: EXPERIMENTAL
Intervention: Touch screen system
Number of subjects: 875

Group type: COMPARATOR
Intervention: Leaflet information only
Number of subjects: 875
Study: 8959424

Group type: EXPERIMENTAL
Intervention: EMDR (Eye Movement Desensitization and Reprocessing)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo (visual non-movement)
Number of subjects: 28
Study: 7827632

Group type: EXPERIMENTAL
Intervention: Weight-bearing exercises
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Nonweight-bearing exercises
Number of subjects: 14

Group type: COMPARATOR
Intervention: Lachman's evaluation
Number of subjects: 14
Study: 3277558

Group type: EXPERIMENTAL
Intervention: Psyllium hydrophilic mucilloid (3.4 g, three doses per day)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo (cellulose)
Number of subjects: 26
Study: 30267954

Group type: EXPERIMENTAL
Intervention: Interaction with an anti-fat peer
Number of subjects: 146

Group type: COMPARATOR
Intervention: Interaction with an unbiased peer
Number of subjects: 146
Study: 28095881

Group type: EXPERIMENTAL
Intervention: High ferritin FCM
Number of subjects: 353

Group type: EXPERIMENTAL
Intervention: Low ferritin FCM
Number of subjects: 353

Group type: COMPARATOR
Intervention: Oral iron
Number of subjects: 353
Study: 24835412

Group type: EXPERIMENTAL
Intervention: Depressive rumination
Number of subjects: 0

Group type: COMPARATOR
Intervention: Distraction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls (CTL)
Number of subjects: 0
Study: 23158515

Group type: EXPERIMENTAL
Intervention: scGOS/lcFOS (0.8 g/100 ml)
Number of subjects: 92
Study: 20850959

Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg once daily (PM)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Indacaterol 300 μg once daily (AM)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Salmeterol 50 μg twice daily
Number of subjects: 96

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study: 16891005

Group type: EXPERIMENTAL
Intervention: Excimer laser coronary angioplasty (ELCA)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Balloon angioplasty and stent implantation alone (Control)
Number of subjects: 27
Study: 16258919

Group type: EXPERIMENTAL
Intervention: Supervised exercise 3 times weekly for 4 months
Number of subjects: 45

Group type: COMPARATOR
Intervention: Nonintervention control group
Number of subjects: 45
Study: 12406669

Group type: EXPERIMENTAL
Intervention: Inhaled formoterol (12 micro g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled salbutamol (200 micro g)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Inhaled salmeterol (50 micro g)
Number of subjects: 10
Study: 11247067

Group type: EXPERIMENTAL
Intervention: Tamsulosin 0.4 mg administered daily for 12 to 24 weeks
Number of subjects: 310
Study: 7972972

Group type: EXPERIMENTAL
Intervention: Nedocromil sodium (8 mg four times daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29
Study: 2732064

Group type: EXPERIMENTAL
Intervention: Know Your Body (KYB) program
Number of subjects: 1041

Group type: EXPERIMENTAL
Intervention: Know Your Body (KYB) program (best teachers)
Number of subjects: 1041

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1041
Study: 31909908

Group type: EXPERIMENTAL
Intervention: SCARE predictive scale
Number of subjects: 902
Study: 31286649

Group type: EXPERIMENTAL
Intervention: Non-resorbable membranes (Ti-PTFE)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Resorbable membranes with titanium mesh (Collagen plus Ti-mesh)
Number of subjects: 40
Study: 29246240

Group type: EXPERIMENTAL
Intervention: Plasma hs‐cTnI concentrations
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: New LGE
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Clinical peri‐operative type 5 myocardial infarction
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Magnitude of LGE
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Systemic humoral inflammatory biomarkers
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: USPIO‐defined cellular myocardial inflammation
Number of subjects: 87
Study: 26286548

Group type: EXPERIMENTAL
Intervention: Computer-based cognitive flexibility training (58 half-hour sessions over 12 weeks)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Mock training (active control group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy elderly (received the same training)
Number of subjects: 0
Study: 21554710

Group type: EXPERIMENTAL
Intervention: Flaxseed supplementation (40 g daily for 12 weeks)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Wheat bran supplementation (40 g daily for 12 weeks)
Number of subjects: 9
Study: 17909090

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 60
Study: 17249841

Group type: EXPERIMENTAL
Intervention: Short questionnaire
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Long questionnaire
Number of subjects: 0
Study: 12839281

Group type: EXPERIMENTAL
Intervention: DTwPHib vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: DTwP + Hib
Number of subjects: 0
Study: 11125709

Group type: EXPERIMENTAL
Intervention: Sentence Repetition test (SR)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: New normative data for SR
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clinical group performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sensitivity and specificity tests of SR
Number of subjects: 0
Study: 9358531

Group type: EXPERIMENTAL
Intervention: Intraperitoneal clindamycin (20 mg/kg body weight, four times per day)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Oral clindamycin (20 mg/kg body weight, three times per day)
Number of subjects: 100
Study: 1544690

Group type: EXPERIMENTAL
Intervention: Evening shift (1600-2400 hours)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Night shift (0000-0800 hours)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Day shift (0800-1600 hours)
Number of subjects: 6
Study: 2580422

Group type: COMPARATOR
Intervention: Zimeldine
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Alaproclate
Number of subjects: 24
Study: 30527876

Group type: EXPERIMENTAL
Intervention: Mimycx virtual games
Number of subjects: 79
Study: 29530072

Group type: COMPARATOR
Intervention: Conventional therapy (CT) alone (S1)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conventional therapy (CT) with extracorporeal hemoperfusion therapy (HCT) (S2)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 0
Study: 27055193

Group type: EXPERIMENTAL
Intervention: Weight-loss diet interventions (4 diet groups with varying macronutrient intakes)
Number of subjects: 768

Group type: EXPERIMENTAL
Intervention: Weight-loss diet interventions
Number of subjects: 768
Study: 25304851

Group type: EXPERIMENTAL
Intervention: 1% cidofovir (gel, 10 g tube, applied for 6 weeks)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: 5% imiquimod (250 mg sachet, self-applied three times a week for a maximum of 24 weeks)
Number of subjects: 180

Group type: COMPARATOR
Intervention: 1% cidofovir
Number of subjects: 180

Group type: COMPARATOR
Intervention: 5% imiquimod
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 180
Study: 22502844

Group type: EXPERIMENTAL
Intervention: Kata techniques training (exercise group, n=15)
Number of subjects: 30

Group type: COMPARATOR
Intervention: No-exercise control group (n=15)
Number of subjects: 30
Study: 19939985

Group type: EXPERIMENTAL
Intervention: Multiple RDA multivitamins
Number of subjects: 1129

Group type: COMPARATOR
Intervention: Single RDA multivitamins
Number of subjects: 1129
Study: 17852477

Group type: EXPERIMENTAL
Intervention: Blueberry nutritional supplement
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: COMPARATOR
Intervention: Blueberry nutritional supplement and Placebo
Number of subjects: 12
Study: 15994013

Group type: EXPERIMENTAL
Intervention: Sterile lubricant (KY-Jelly) and sterile razor debridement
Number of subjects: 20

Group type: COMPARATOR
Intervention: Conventional method
Number of subjects: 20
Study: 15463813

Group type: EXPERIMENTAL
Intervention: TLC C‐53 (prostaglandin E(1) associated with egg phosphatidylcholine liposomes) at doses of 0.15-1.8 microg/kg by 4 x 1-h infusions
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: TLC C‐53 (prostaglandin E(1) associated with egg phosphatidylcholine liposomes)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 10340731

Group type: EXPERIMENTAL
Intervention: Acute pancreatitis patients (mild and severe)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Healthy subjects
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Patients with electrocardiographic abnormalities
Number of subjects: 56
Study: 8935906

Group type: EXPERIMENTAL
Intervention: Explicitly informed subjects
Number of subjects: 0

Group type: COMPARATOR
Intervention: Uninformed subjects
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both informed and uninformed subjects
Number of subjects: 0
Study: 2015155

Group type: EXPERIMENTAL
Intervention: Identification of L4 by physically constructing Tuffier's line
Number of subjects: 50
Study: 6212554

Group type: EXPERIMENTAL
Intervention: Etodolac 100 mg
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Etodolac 200 mg
Number of subjects: 146

Group type: EXPERIMENTAL
Intervention: Etodolac 400 mg
Number of subjects: 146

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146

Group type: COMPARATOR
Intervention: Aspirin 650 mg
Number of subjects: 146
Study: 30850837

Group type: EXPERIMENTAL
Intervention: Total protein intake (0.90 g · kg‐1 · d‐1)
Number of subjects: 1561

Group type: EXPERIMENTAL
Intervention: Animal protein intake
Number of subjects: 1561

Group type: EXPERIMENTAL
Intervention: Plant protein intake
Number of subjects: 1561
Study: 28662466

Group type: EXPERIMENTAL
Intervention: Performance-contingent reward with informationally administered reward
Number of subjects: 84

Group type: COMPARATOR
Intervention: Task-contingent reward with no feedback (Control)
Number of subjects: 84
Study: 25800412

Group type: EXPERIMENTAL
Intervention: iGEL
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: LMA
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: AWS
Number of subjects: 38

Group type: EXPERIMENTAL
Intervention: MCL
Number of subjects: 38
Study: 24859205

Group type: EXPERIMENTAL
Intervention: IFL (irinotecan, fluorouracil, and leucovorin)
Number of subjects: 615

Group type: COMPARATOR
Intervention: Fluorouracil and leucovorin
Number of subjects: 615

Group type: EXPERIMENTAL
Intervention: Not applicable
Number of subjects: 615
Study: 22044486

Group type: EXPERIMENTAL
Intervention: Involving relatives in relapse prevention planning
Number of subjects: 52
Study: 19716637

Group type: EXPERIMENTAL
Intervention: Lower limb strength training (12 weeks, 3 days per week)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 27
Study: 16443257

Group type: EXPERIMENTAL
Intervention: Unfractionated heparin plus phenprocoumon
Number of subjects: 248
Study: 14715215

Group type: EXPERIMENTAL
Intervention: Counseling provided by physicians in the office setting
Number of subjects: 392
Study: 11434052

Group type: EXPERIMENTAL
Intervention: LMWH (Low Molecular Weight Heparin)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: GP IIb/IIIa inhibitors
Number of subjects: 0

Group type: COMPARATOR
Intervention: Proven therapies
Number of subjects: 0
Study: 8980774

Group type: EXPERIMENTAL
Intervention: Delavirdine mesylate (400 mg)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Didanosine (125 to 200 mg buffered tablets)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Delavirdine followed by didanosine (1 h later)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Concurrent administration of delavirdine and didanosine
Number of subjects: 12
Study: 8356961

Group type: EXPERIMENTAL
Intervention: Standard Schwarz vaccine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: High-titer Edmonston-Zagreb vaccine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: High-titer Schwarz vaccine
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Standard measles vaccine
Number of subjects: 3
Study: 3318426

Group type: EXPERIMENTAL
Intervention: Nabumetone, 1,000 mg at bedtime
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Nabumetone
Number of subjects: 46

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study: 29438818

Group type: EXPERIMENTAL
Intervention: Hypertonic saline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Eucapnic dry air
Number of subjects: 60
Study: 27309537

Group type: EXPERIMENTAL
Intervention: N-acetyl-cysteine (NAC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study: 24814592

Group type: EXPERIMENTAL
Intervention: Tailored smoking cessation advice (intervention group)
Number of subjects: 254

Group type: COMPARATOR
Intervention: Control group (standard advice)
Number of subjects: 254
Study: 22290270

Group type: EXPERIMENTAL
Intervention: IV iron polymaltose (500 mg single dose)
Number of subjects: 104

Group type: COMPARATOR
Intervention: PO ferrous sulfate (210 mg elemental iron daily, continuously)
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: IV iron polymaltose
Number of subjects: 104

Group type: COMPARATOR
Intervention: PO ferrous sulfate
Number of subjects: 104
Study: 20199680

Group type: EXPERIMENTAL
Intervention: Web-based decision aid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Print-based decision aid
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both web- and print-based decision aids
Number of subjects: 0
Study: 18058417

Group type: EXPERIMENTAL
Intervention: Telephone calls to patients after discharge
Number of subjects: 339

Group type: COMPARATOR
Intervention: No planned contact (control group)
Number of subjects: 339
Study: 16084152

Group type: EXPERIMENTAL
Intervention: tenecteplase combined with tirofiban
Number of subjects: 409

Group type: COMPARATOR
Intervention: full-dose tenecteplase alone
Number of subjects: 409
Study: 12360587

Group type: EXPERIMENTAL
Intervention: Histochrome 100 mg administered 10 min before and 1 hour after thrombolytic therapy (group 1A)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Histochrome 100 mg on disease day 1 followed by 100 mg/day for 10 days (group 1B)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Thrombolysis without prophylactic histochrome (control group)
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Histochrome groups (1A and 1B)
Number of subjects: 86
Study: 10094287

Group type: EXPERIMENTAL
Intervention: Employment in the electrochemical factory (high exposure group)
Number of subjects: 1800

Group type: COMPARATOR
Intervention: Non-workers (low exposure group)
Number of subjects: 1800
Study: 7756063

Group type: EXPERIMENTAL
Intervention: Intravenous isosorbide dinitrate
Number of subjects: 316

Group type: COMPARATOR
Intervention: Sustained release isosorbide mononitrate
Number of subjects: 316
Study: 2354706

Group type: EXPERIMENTAL
Intervention: Low-frequency transcutaneous nerve stimulation (TNS) for 20 minutes
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 16
Study: 681029

Group type: EXPERIMENTAL
Intervention: Hypnosis condition
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Nonhypnosis condition
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: High susceptible Ss (scoring 8-12)
Number of subjects: 36
Study: 31331199

Group type: EXPERIMENTAL
Intervention: Interprofessional education (IPE) program
Number of subjects: 291

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 291
Study: 28144877

Group type: EXPERIMENTAL
Intervention: Verbal fluency tasks designed to decrease initiation impairment
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Verbal fluency tasks designed to enhance initiation impairment
Number of subjects: 2

Group type: COMPARATOR
Intervention: Verbal fluency tasks (general)
Number of subjects: 2
Study: 24706022

Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks (PNB) with an indwelling femoral nerve catheter and a single shot sciatic block
Number of subjects: 160

Group type: COMPARATOR
Intervention: Periarticular injection (PAI) using ropivacaine, epinephrine, ketorolac, and morphine
Number of subjects: 160

Group type: COMPARATOR
Intervention: Periarticular injection (PAI)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Peripheral nerve blocks (PNB)
Number of subjects: 160
Study: 23838989

Group type: EXPERIMENTAL
Intervention: Clear speech
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Loud condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Slow condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Habitual condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clear condition
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Peripheral and nonperipheral vowel pairs across conditions
Number of subjects: 0
Study: 21990828

Group type: EXPERIMENTAL
Intervention: Mynx M5 (extravascular synthetic sealant)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Angio-Seal Evolution (self-tightening suture)
Number of subjects: 64
Study: 18707755

Group type: EXPERIMENTAL
Intervention: Normoglycemic treatment (4.72 mmol/L)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Moderate hyperglycemia (11.1 mmol/L)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High-grade hyperglycemia (16.7 mmol/L)
Number of subjects: 12